Hypodermoclysis (HDC) for symptom control vs. the Edmonton Injector (EI).

R. L. Fainsinger, E. Bruera

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

Hypodermoclysis (HDC) is a well-known method of providing symptom control in terminally ill patients. In this article we make reference to two previous reports describing our use of HDC and a new method of subcutaneous narcotic delivery called the Edmonton Injector (EI). The rationale for using HDC mainly for rehydration and the EI when subcutaneous narcotics are needed is explored. The controversy surrounding the treatment of dehydration in the terminally ill is examined. Finally, the advantages on our palliative care unit of the convenience, increased flexibility, and cost and time saving of these two treatment methods are discussed.

Original languageEnglish (US)
Pages (from-to)5-8
Number of pages4
JournalJournal of palliative care
Volume7
Issue number4
DOIs
StatePublished - 1991
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Hypodermoclysis (HDC) for symptom control vs. the Edmonton Injector (EI).'. Together they form a unique fingerprint.

Cite this